Bli medlem
Bli medlem

Du är här


Prothena Announces Appointment of Gene G. Kinney as Chief Operating Officer

G. Kinney as Chief Operating Officer

DUBLIN, Ireland, 2016-09-06 22:05 CEST (GLOBE NEWSWIRE) --
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology
company focused on the discovery, development, and commercialization of novel
protein immunotherapies, today announced the promotion of Gene G. Kinney, PhD
to the position of Chief Operating Officer (COO). In this newly created
position, Dr. Kinney will be responsible for an integrated research,
development and commercial organization, and several additional key
organizational functions within the company. Dr. Kinney also retains his title
and responsibilities as Chief Scientific Officer. Dr. Kinney had held the
position of Chief Scientific Officer and Head of Research and Development since
Prothena was established in December 2012, leading the team responsible for
advancing a robust clinical pipeline into late-stage clinical development as
well as generating novel antibody targets in discovery.

“Gene’s appointment to this expanded role underscores not only his exceptional
scientific and business leadership, but also the exciting growth path we are
setting for Prothena,” commented Dale Schenk, PhD, President and Chief
Executive Officer of Prothena. “As one of our founding executive team members
responsible for helping to establish the company and advance a pipeline of
novel protein immunotherapies, Gene is uniquely qualified to guide our
continued growth as a fully integrated research, development and commercial
organization. I very much look forward to working with him on these critical

“Gene is a highly regarded, creative, and thoughtful leader who has played a
key role in the success Prothena has experienced to date,” noted Lars G. Ekman,
MD, PhD, Chairman of the Prothena Board of Directors. “The Prothena Board is
delighted to continue working with Gene in this new leadership role.”

Dr. Kinney is an experienced biotechnology executive and has held positions
across pharmaceutical, biotechnology and academic organizations. In positions
of increasing scope, Dr. Kinney has held responsibility for overseeing
portfolio strategy, leading R&D teams, and supporting commercial product
launches. Before joining Prothena, Dr. Kinney was Senior Vice President of
Pharmacological Sciences at Elan Pharmaceuticals, Inc. where he held several
senior roles in research and development from 2009 through 2012. Between 2010
and 2012, Dr. Kinney also served as Head of Nonclinical Research for Janssen
Alzheimer Immunotherapy R&D. From 2001 to 2009, he was Senior Director, Head of
Central Pharmacology and acting lead for Bioanalytics & Pathology at Merck
Research Laboratories. Dr. Kinney also held positions at Bristol-Myers Squibb
and was an Assistant Professor at the Emory University School of Medicine,
Department of Psychiatry and Behavioral Sciences.

Dr. Kinney earned his B.A. from Bloomsburg University and his M.A. and Ph.D.
from Florida Atlantic University.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company
seeking to fundamentally change the course of progressive diseases with its
clinical pipeline of novel therapeutic antibodies. Fueled by its deep
scientific understanding built over decades of research in protein misfolding
and cell adhesion — the root causes of many serious or currently untreatable
amyloid and inflammatory diseases — Prothena has advanced several drug
candidates into clinical trials while pursuing discovery of additional novel
therapies. Our pipeline of antibody-based product candidates targets a number
of potential indications including AL amyloidosis (NEOD001), Parkinson's
disease and other related synucleinopathies (PRX002) and inflammatory diseases,
including psoriasis (PRX003), and ATTR amyloidosis (PRX004). For more
information, please visit the company's web site at

Investors: Tran Nguyen, CFO

Media: Ellen Rose

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.